• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

卡氮芥的稳定性与乙醇浓度和温度的关系。

BCNU stability as a function of ethanol concentration and temperature.

作者信息

Tepe P, Hassenbusch S J, Benoit R, Anderson J H

机构信息

Department of Neurosurgery, Cleveland Clinic Foundation, Ohio.

出版信息

J Neurooncol. 1991 Apr;10(2):121-7. doi: 10.1007/BF00146872.

DOI:10.1007/BF00146872
PMID:1895160
Abstract

BCNU is increasingly used in low ethanol (ETOH) concentrations, 5% dextrose-water (D5W), or normal saline (NS) solutions, especially for intra-arterial and prolonged (e.g., 3 day) intravenous (IV) infusions. Little work, however, has been done to evaluate BCNU decomposition rates in concentrations, diluents, and temperatures similar to those employed clinically. This study examined BCNU solutions in ETOH, NS, and D5W to evaluate, conclusively, initial recovery and decomposition rates in these three diluents. Initial BCNU recovery rates were: 95.6 +/- 0.3% (100% D5W), 89.6 +/- 0.5% (15% ETOH), and 85.2 +/- 0.5% (NS) (P less than 0.001). Study of all solutions revealed no measurable BCNU decomposition over 24 hrs (0 degrees C) and no significant difference in decomposition rates between any of the diluents (19.5 degrees C). At 37 degrees C, the solutions showed different half-lives: 14.3 +/- 0.19 hrs (15% ETOH), 10.6 +/- 0.02 hrs (10% ETOH), 8.2 +/- 0.21 hrs (5% ETOH), 7.3 +/- 0.06 hrs (NS), and 6.8 +/- 0.07 hrs (D5W) (P less than 0.001). Decomposition rates between all three temperatures (19.5 degrees C, 37 degrees C, and 50 degrees C) were significantly different (P less than 0.01) for each diluent. Dissolving BCNU powder into either D5W or NS required only 5 min when hand-shaken at body temperature. This study of initial recovery and decomposition rates suggests that, although BCNU decomposition rates were significantly increased at body temperature (37 degrees C), it was quite low and essentially unaffected by different diluents at room temperature (i.e., 19.5 degrees C).(ABSTRACT TRUNCATED AT 250 WORDS)

摘要

卡氮芥越来越多地用于低乙醇(ETOH)浓度、5%葡萄糖水(D5W)或生理盐水(NS)溶液中,尤其是用于动脉内输注和长时间(如3天)静脉内(IV)输注。然而,很少有研究评估卡氮芥在与临床使用相似的浓度、稀释剂和温度下的分解率。本研究检测了卡氮芥在乙醇、生理盐水和5%葡萄糖水中的溶液,以最终评估这三种稀释剂中的初始回收率和分解率。卡氮芥的初始回收率分别为:95.6±0.3%(100% D5W)、89.6±0.5%(15% ETOH)和85.2±0.5%(NS)(P<0.001)。对所有溶液的研究表明,在24小时(0℃)内未检测到卡氮芥分解,且任何稀释剂之间的分解率在19.5℃时无显著差异。在37℃时,溶液显示出不同的半衰期:14.3±0.19小时(15% ETOH)、10.6±0.02小时(10% ETOH)、8.2±0.21小时(5% ETOH)、7.3±0.06小时(NS)和6.8±0.07小时(D5W)(P<0.001)。每种稀释剂在所有三个温度(19.5℃、37℃和50℃)之间的分解率均有显著差异(P<0.01)。在体温下手动摇晃时,将卡氮芥粉末溶解于D5W或NS中仅需5分钟。这项关于初始回收率和分解率的研究表明,虽然卡氮芥在体温(37℃)下的分解率显著增加,但分解率相当低,并且在室温(即19.5℃)下基本上不受不同稀释剂的影响。(摘要截断于250字)

相似文献

1
BCNU stability as a function of ethanol concentration and temperature.卡氮芥的稳定性与乙醇浓度和温度的关系。
J Neurooncol. 1991 Apr;10(2):121-7. doi: 10.1007/BF00146872.
2
BCNU solubility and toxicity in the treatment of malignant astrocytomas.
J Neurosurg. 1984 Jun;60(6):1134-7. doi: 10.3171/jns.1984.60.6.1134.
3
Stability of norepinephrine infusions prepared in dextrose and normal saline solutions.在葡萄糖溶液和生理盐水中制备的去甲肾上腺素输注液的稳定性。
Can J Anaesth. 2008 Mar;55(3):163-7. doi: 10.1007/BF03016090.
4
Stability of Reconstituted Telavancin Drug Product in Frozen Intravenous Bags.重组替考拉宁药品在冷冻静脉输液袋中的稳定性。
Hosp Pharm. 2015 Jul;50(7):609-14. doi: 10.1310/hpj5007-609. Epub 2015 Jul 20.
5
Extended stability of pantoprazole for injection in 0.9% sodium chloride or 5% dextrose at 4°c and 23°c.注射用泮托拉唑在4℃和23℃下于0.9%氯化钠或5%葡萄糖溶液中的稳定性延长情况。
Can J Hosp Pharm. 2009 Mar;62(2):135-41. doi: 10.4212/cjhp.v62i2.442.
6
Internal morphology of poly(D,L-lactide-co-glycolide) BCNU-loaded microspheres. Influence on drug stability.载有卡莫司汀的聚(D,L-丙交酯-共-乙交酯)微球的内部形态。对药物稳定性的影响。
Eur J Pharm Biopharm. 1998 Jan;45(1):31-9. doi: 10.1016/S0939-6411(97)00120-3.
7
Resorbable polymer microchips releasing BCNU inhibit tumor growth in the rat 9L flank model.释放卡莫司汀的可吸收聚合物微芯片抑制大鼠9L侧腹模型中的肿瘤生长。
J Control Release. 2007 Nov 6;123(2):172-8. doi: 10.1016/j.jconrel.2007.08.003. Epub 2007 Aug 15.
8
Stability of norepinephrine solutions in normal saline and 5% dextrose in water.去甲肾上腺素溶液在生理盐水和5%葡萄糖水中的稳定性。
Can J Hosp Pharm. 2010 Mar;63(2):113-8. doi: 10.4212/cjhp.v63i2.896.
9
Stability of commonly used antibiotic solutions in an elastomeric infusion device.常用抗生素溶液在弹性输液装置中的稳定性。
Can J Hosp Pharm. 2010 May;63(3):212-24. doi: 10.4212/cjhp.v63i3.917.
10
Stability of fosphenytoin sodium with intravenous solutions in glass bottles, polyvinyl chloride bags, and polypropylene syringes.磷苯妥英钠在玻璃瓶、聚氯乙烯袋和聚丙烯注射器中的静脉输液稳定性。
Ann Pharmacother. 1997 May;31(5):553-9. doi: 10.1177/106002809703100505.

引用本文的文献

1
Efficacy of interstitial continuous vincristine infusion in a bioluminescent rodent intracranial tumor model.间质连续长春新碱输注在生物发光啮齿动物颅内肿瘤模型中的疗效。
J Neurooncol. 2012 Jan;106(2):261-70. doi: 10.1007/s11060-011-0680-8. Epub 2011 Aug 14.
2
Resorbable polymer microchips releasing BCNU inhibit tumor growth in the rat 9L flank model.释放卡莫司汀的可吸收聚合物微芯片抑制大鼠9L侧腹模型中的肿瘤生长。
J Control Release. 2007 Nov 6;123(2):172-8. doi: 10.1016/j.jconrel.2007.08.003. Epub 2007 Aug 15.
3
In vitro characterization of the myelotoxicity of cyclopentenyl cytosine.

本文引用的文献

1
Distribution of Bratton-Marshall-positive material in mice following intravenous injections of nitrosoureas.静脉注射亚硝基脲后小鼠体内布拉顿 - 马歇尔阳性物质的分布情况。
Cancer Chemother Pharmacol. 1980;4(4):243-8. doi: 10.1007/BF00255268.
2
Solvent systems for intracarotid 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU) infusion.用于颈动脉内注入1,3-双(2-氯乙基)-1-亚硝基脲(卡莫司汀)的溶剂系统。
Neurosurgery. 1983 May;12(5):512-4. doi: 10.1227/00006123-198305000-00006.
3
Intra-arterial BCNU chemotherapy for treatment of malignant gliomas of the central nervous system.
环戊烯基胞嘧啶骨髓毒性的体外特性研究
Cancer Chemother Pharmacol. 1994;34(2):103-8. doi: 10.1007/BF00685926.
4
Test for chemotherapeutic sensitivity of cerebral gliomas: use of colorimetric MTT assay.脑胶质瘤化疗敏感性检测:比色法MTT检测的应用
J Neurooncol. 1992 Sep;14(1):19-35. doi: 10.1007/BF00170942.
动脉内注射卡氮芥化疗治疗中枢神经系统恶性胶质瘤。
J Neurosurg. 1984 Sep;61(3):423-9. doi: 10.3171/jns.1984.61.3.0423.
4
BCNU solubility and toxicity in the treatment of malignant astrocytomas.
J Neurosurg. 1984 Jun;60(6):1134-7. doi: 10.3171/jns.1984.60.6.1134.
5
Orbital angiographic changes after intracarotid BCNU chemotherapy.经颈动脉注射卡氮芥化疗后的眼眶血管造影改变。
AJNR Am J Neuroradiol. 1984 Jan-Feb;5(1):55-8.
6
Clinical trials with 1,3-bis(2-chloroethyl)-1-nitrosourea, NSC-409962.
Cancer Res. 1965 Dec;25(11):1876-81.
7
Colorimetric method for the determination of 1,3-bis(2-chloroethyl)-1-nitrosourea.1,3-双(2-氯乙基)-1-亚硝基脲的比色测定法
J Pharm Sci. 1965 May;54(5):809-10. doi: 10.1002/jps.2600540538.
8
1,3-bis(2-chloroethyl)-1-nitrosourea (bcnu) and other nitrosoureas in cancer treatment: a review.
Adv Cancer Res. 1972;16:273-332. doi: 10.1016/s0065-230x(08)60343-7.
9
Decomposition of BCNU (1,3-bis(2-chloroethyl)-1-nitrosourea) in aqueous solution.卡莫司汀(1,3-双(2-氯乙基)-1-亚硝基脲)在水溶液中的分解
Biochem Biophys Res Commun. 1974 Sep 23;60(2):515-20. doi: 10.1016/0006-291x(74)90270-8.
10
Neurological deficit after carotid infusion of cisplatin and 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU) for malignant glioma: an analysis of risk factors.
Neurosurgery. 1986 Nov;19(5):779-83. doi: 10.1227/00006123-198611000-00010.